Inventor · disambiguated record
Yuanyuan Jiang
Also filed as: JIANG YUANYUAN
14 granted patents·6 pending applications·55 citations·filing 2017–2024
89Inventor score
Top patents by PatentIndex Score
20 records- 0195US11919918B2P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2022·Granted Mar 5, 2024·6 cites·20 claims
- 0293US11390609B2Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2018·Granted Jul 19, 2022·12 cites·28 claims
- 0393US10329282B2Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2017·Granted Jun 25, 2019·13 cites·45 claims
- 0493US10323023B2Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2017·Granted Jun 18, 2019·14 cites·71 claims
- 0591US12180243B2Receptor inhibitor, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2022·Granted Dec 31, 2024·2 cites·74 claims
- 0689US11414444B2P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2018·Granted Aug 16, 2022·5 cites·15 claims
- 0786US11453690B2Receptor inhibitor, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2019·Granted Sep 27, 2022·3 cites·50 claims
- 0880US12509479B2P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2024·Granted Dec 30, 2025·0 cites·17 claims
- 0979US2025066398A1Receptor inhibitor, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1067US11939578B2Double-stranded RNA molecule targeting CKIP-1 and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Granted Mar 26, 2024·0 cites·14 claims
- 1162US11155819B2Double-stranded RNA molecule targeting CKIP-1 and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2018·Granted Oct 26, 2021·0 cites·20 claims
- 1262US2023030115A1Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1353US12485108B2Method for treating fatty liver disease and/or steatohepatitisBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Dec 2, 2025·0 cites·17 claims
- 1450US2023212160A12,4,6-tri-substituted pyrimidine compounds as atr kinase inhibitorsBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1548US2022211703A1Method for treating cough by using diaminopyrimidine compoundBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 1646US12398118B2Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2019·Granted Aug 26, 2025·0 cites·13 claims
- 1746US2022306659A1Compound inhibiting and inducing degradation of egfr and alkBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 1845US12410192B2Compound for inhibiting and inducing degradation of EGFR kinaseBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 9, 2025·0 cites·20 claims
- 1943US11905274B2Receptor inhibitors, pharmaceutical compositions comprising the same and use thereofBEIJING TIDE PHARMACEUTICAL CO LTD·Filed 2019·Granted Feb 20, 2024·0 cites·44 claims
- 2038US2023326996A1Gallium nitride-based high electron mobility transistor epitaxial wafer and preparation method thereforHC SEMITEK ZHEJIANG CO LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yuanyuan Jiang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →